治疗肝内胆管癌新药:泛FGFR抑制剂福巴替尼
A new drug in treating intrahepatic cholangiocarcinoma:FGFR1-4 inhibitor futibatinib
狄潘潘 1邢晓勤 1梁海 1贾淑云1
作者信息
- 1. 安徽医科大学附属亳州医院药学部,安徽亳州 236800
- 折叠
摘要
肝内胆管癌(ICC)是一种发生于胆管系统的恶性肿瘤,起病隐匿,患者总体预后较差,死亡率较高.福巴替尼是一种泛成纤维细胞生长因子受体(FGFR)抑制剂,于2022年被美国食品和药物管理局批准上市,用于既往治疗过的、不可切除的局部晚期或转移性且伴有FGFR2基因融合或其他重排的ICC成年患者.Ⅰ期和Ⅱ期临床试验表明,福巴替尼对ICC具有良好的治疗效果,可显著提高ICC患者的客观缓解率并延长患者的生存时间;其常见不良事件包括高磷血症、腹泻、便秘及口干等,不良事件发生率较高.
Abstract
Intrahepatic cholangiocarcinoma(ICC)is a malignant tumor that occurs in the biliary system,with a hidden onset,poor overall prognosis and high mortality.Futibatinib is a fibroblast growth factor receptor(FGFR)1-4 inhibitor,which was approved by the U.S.Food and Drug Administration in 2022 for the treatment of adult patients with previously treated,unresectable,locally advanced or metastatic ICC with FGFR2 gene fusions or other rearrangements.PhaseⅠ and Ⅱ clinical trials have shown that futibatinib has good clinical effect on ICC,which can significantly improve the objective response rate and prolong the survival time of ICC patients.The common adverse events include hyperphosphatemia,diarrhea,constipation,and dry mouth,with a high incidence of adverse events.
关键词
肝内胆管癌/福巴替尼/成纤维细胞生长因子/抗肿瘤药Key words
intrahepatic cholang iocarcinoma/futibatinib/fibroblast growth factors/antineoplastic agents引用本文复制引用
基金项目
亳州市人民医院院级科研项目(by2023006)
安徽医科大学项目(2023xkj091)
出版年
2024
NETL
NSTL
万方数据